Richmond Pharmacology announces its attendance at TIDES Europe 2025 in Basel, one of the leading global conferences dedicated to oligonucleotide- and peptide-based therapeutics.
This year’s meeting will bring together experts from across the world to discuss advances in discovery, development, and clinical translation of RNA, DNA, and peptide therapeutics.
Representing Richmond Pharmacology:
• Stephen Wilkinson, Business Development Manager
Stephen looks forward to engaging with industry leaders, researchers, and clinical partners to explore opportunities in:
• Early-phase trials for oligonucleotide and peptide therapies
• Rare and metabolic disease clinical research
• Regulatory strategy and scientific advice
• Innovative patient recruitment models
• Adaptive and patient-centric trial design
If you are attending TIDES Europe and would like to learn how Richmond Pharmacology can support your oligonucleotide and peptide therapeutic development, we welcome you to connect with us during the event.
For meeting requests or collaboration enquiries:
📧info@richmondpharmacology.com
Learn more about the event: TIDES Europe: Oligonucleotide and Peptide Therapeutics
.svg){kind=small}
.avif)
